We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Advanced Blood Test Detects and Analyzes Circulating Tumor Cells

By LabMedica International staff writers
Posted on 13 Feb 2012
An advanced blood test detects and analyzes circulating tumor cells (CTCs) from cancer patients.

The new test, called high definition CTC (HD-CTC), labels cells in a patient's blood sample in a way that distinguishes possible CTCs from ordinary red and white blood cells. More...
A digital microscope and an image-processing algorithm are used to isolate the suspect cells with sizes and shapes (morphologies) unlike those of healthy cells. A pathologist can examine the images of the suspected CTCs to eliminate false positives and note their morphologies.

Scientists from The Scripps Research Institute (TSRI; La Jolla, CA, USA), Scripps Health, and collaborating cancer physicians successfully demonstrated the effectiveness of the blood test. Five new studies resulted from the collaboration and demonstrated the new test's accuracy and effectiveness for a number of different cancer types. The studies also began to explore the utility of the technology for diagnosing and monitoring patients and improving cancer research in the lab.

"It is a next-generation technology," said Scripps' Associate Prof. Peter Kuhn, PhD, senior investigator of the new studies and primary inventor of the high-definition blood test. "It significantly boosts our ability to monitor, predict, and understand cancer progression, including metastasis, which is the major cause of death for cancer patients."

Whereas other tests for CTCs typically use enrichment steps in which suspected CTCs are concentrated--methods that can inadvertently exclude some types of CTCs--the new studies show HD-CTC works well as a no-cell-left-behind process and enables a more complete analysis.

Prof. Kuhn emphasized that the basic setup can be easily modified with different cell-labeling and image-processing techniques. He and his colleagues will study the use of HD-CTC as a potential screening test and develop it further for use in clinical monitoring and cancer research. Prof. Kuhn has founded a San Diego-based biotechnology company, Epic Sciences, Inc. (CA, USA) to develop HD-CTC commercially for companion diagnostic products in personalized cancer care.

The studies were published in the February 2012 edition of the journal Physical Biology.

Related Links:
The Scripps Research Institute
Epic Sciences



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Platelet Function Analyzer
PL-12
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image

FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing

Urinary tract infections are among the most common bacterial infections and a major driver of antibiotic prescribing, yet culture-based workflows can take days to produce results. Treatment often begins... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.